BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC)
| dc.contributor.author | Debled, M. | |
| dc.contributor.author | Hegg, R. | |
| dc.contributor.author | Cardoso, F. | |
| dc.contributor.author | Ringeisen, F. | |
| dc.contributor.author | Lin, J. | |
| dc.contributor.author | Ridolfi, A. | |
| dc.contributor.author | Manlius, C. | |
| dc.contributor.author | Gradishar, W. J. | |
| dc.contributor.author | Ozguroglu, M. | |
| dc.contributor.author | Royce, M. | |
| dc.contributor.author | Villanueva, C. | |
| dc.contributor.author | Bachelot, T. | |
| dc.contributor.author | Azevedo, S. | |
| dc.contributor.author | Melo Cruz, F. | |
| dc.date.accessioned | 2021-03-04T17:55:49Z | |
| dc.date.available | 2021-03-04T17:55:49Z | |
| dc.identifier.citation | Royce M., Villanueva C., Ozguroglu M., Bachelot T., Azevedo S., Melo Cruz F., Hegg R., Debled M., Gradishar W. J. , Manlius C., et al., "BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC)", 41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Danimarka, 7 - 11 Ekim 2016, cilt.27 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_880908ca-09e7-423d-b1c9-a78b2ae811a9 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/92345 | |
| dc.identifier.uri | https://doi.org/10.1093/annonc/mdw365.1 | |
| dc.language.iso | eng | |
| dc.subject | Onkoloji | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Tıp | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | ONKOLOJİ | |
| dc.subject | Klinik Tıp | |
| dc.title | BOLERO-4: Phase 2 trial of first-line everolimus (EVE) plus letrozole (LET) in estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) | |
| dc.type | Bildiri | |
| dc.contributor.department | University Of New Mexico , , | |
| dc.identifier.volume | 27 | |
| dc.contributor.firstauthorID | 150342 |
Files in this item
| Files | Size | Format | View |
|---|---|---|---|
|
There are no files associated with this item. |
|||
This item appears in the following Collection(s)
-
Bildiri [64839]